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The optimal means for detecting and managing liver transplantation (LT) patients with latent tuberculosis (TB) are not well
defined. Our study aims were to (1) determine the frequency and risk factors of latent TB in a large cohort of consecutive
adult LT candidates and (2) determine the safety and efficacy of isoniazid treatment in LT recipients with latent TB. A review
of patients assessed for latent TB by skin testing using purified protein derivative (PPD; January 2004 to September 2008)
or with the interferon-c release assay QuantiFERON-TB Gold (QFT; March 2008 to October 2009) was undertaken. The
baseline clinical features and outcomes of subjects with latent TB and subjects without latent TB were compared. Twenty-
five of 420 subjects (6.0%) were positive for PPD. In comparison, 11 of 119 subjects (9.2%) had a positive QFT assay, and
15 others (13%) had indeterminate results. Both PPD-positive and QFT-positive subjects were less likely to be Caucasian
than subjects without latent TB (p < 0.001). The 3-year survival rate of the 25 LT recipients with latent TB was similar to
that of the 296 LT recipients without latent TB (78.7% versus 74.6%, P ¼ 0.58). Fifteen of the 25 latent TB patients received
isoniazid at a mean of 0.67 months after LT. Although isoniazid was discontinued in 8 subjects because of possible side
effects, none of the 25 latent TB patients developed TB reactivation after transplantation with a mean follow-up of 33
months. In conclusion, both QFT testing and PPD testing demonstrate similar rates of detecting latent TB infection in Amer-
ican LT candidates, but QFT testing also leads to a moderate rate of indeterminate test results. Early isoniazid chemopro-
phylaxis after LT is poorly tolerated and is frequently discontinued. Liver Transpl 17:306-314, 2011. VC 2011 AASLD.
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Nearly one-third of the world’s population has been
previously infected with Mycobacterium tuberculosis
(MTB).1 Because immunosuppression can lead to
severe and life-threatening tuberculosis (TB) reactiva-
tion for solid organ transplant recipients, the identifi-
cation of patients with latent TB is recommended
before transplantation.2 This recommendation is
graded as level III on the basis of expert opinion and
descriptive epidemiology.2 However, there currently is
no gold standard for diagnosing latent TB infection;
detection is based on a patient’s medical history,
tuberculin skin testing using purified protein deriva-
tive (PPD), interferon-c release assays, and chest
X-ray findings. The sensitivity of PPD testing in trans-
plant candidates is suboptimal because of the high
rate of false-negative results in sick patients with
anergy.3 Currently, there are several interferon-c
release assays that are approved for the detection of
the proliferative response of peripheral lymphocytes to
specific MTB antigens.4,5 All these assays, including
the QuantiFERON-TB Gold (QFT) assay (Cellestis, Vic-
toria, Australia), have sensitivity comparable to that
of PPD testing. However, by distinguishing positive
skin test results due to a previous Bacille Calmette-
Guerin (BCG) vaccination or an infection with atypical
mycobacteria from those due to a previous MTB infec-
tion, these assays have potentially improved specific-
ity.6,7 Although QFT testing for latent TB is positive in
0% to 3% of low-risk patient populations, the utility of
QFT testing versus traditional PPD testing for latent
TB in immunocompromised liver transplantation (LT)
candidates is not well described.7-11 The primary aim
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of our study was to determine the incidence, risk fac-
tors, and outcomes for consecutive adult LT candi-
dates with or without latent TB as determined by PPD
and QFT screening tests. Our secondary aim was to
determine the safety and efficacy of isoniazid chemo-
prophylaxis in LT recipients with latent TB infection.
PATIENTS AND METHODS
Patient Population
A retrospective review of consecutive adult patients
who were listed for LT between January 2004 and Oc-
tober 2009 at the University of Michigan and under-
went testing for latent TB infection was undertaken.
The medical records of these patients were searched
after institutional review board approval was obtained
for the following data fields: date of listing; age at list-
ing; gender; ethnicity; liver diagnosis (eg, hepatitis C
or alcohol); Model for End-Stage Liver Disease (MELD)
score at listing; laboratory data at listing (including
INR, bilirubin, creatinine, and white blood cell count);
date of transplant, pretransplant death, or last avail-
able follow-up; results of pretransplant TB testing
(PPD or QFT); preoperative chest imaging results; pre-
vious history of TB therapy; and history of BCG vacci-
nation. In addition, recognized clinical risk factors for
latent TB infection, including occupational exposure,
residence in a high-prevalence country, and a history
of imprisonment or known exposure to active MTB,
were sought.12
For those with positive latent TB test results, the
following data were also extracted: country of origin;
dates and dosing of isoniazid therapy (total number of
days); frequency and reasons for dose reduction; and
serum aspartate aminotransferase, alanine amino-
transferase, alkaline phosphatase, and total bilirubin
levels before, during, and after isoniazid treatment. In
addition, immunosuppressive therapy while the
patient was receiving isoniazid, evidence of TB reacti-
vation, and survival after transplantation were deter-
mined. Immunosuppression consisted of tacrolimus,
mycophenolate mofetil, and prednisone initially and
was tapered to tacrolimus monotherapy by 12 months
whenever possible and particularly in patients with vi-
ral hepatitis. Basiliximab (Simulect, Genentech, Nut-
ley, NJ) induction with a delay in tacrolimus use for 3
to 5 days was used in subjects with renal failure at
the time of transplantation
Testing for Latent TB
A positive TB skin test result is defined as an indu-
ration of 5 mm or more in diameter 48 to 72 hours af-
ter the administration of 5 tuberculin units of intra-
dermal PPD. The PPD test was administered at the
initial evaluation appointment and before placement
on the LT waiting list. The PPD test was interpreted
by nursing staff or a physician either at the trans-
plant center or locally, and results were reported as
positive or negative. Repeat testing to assess for
boosting was not routinely performed. Candida skin
testing for anergy was not completed per the guide-
lines of the Centers for Disease Control and Preven-
tion.13 QFT testing (Cellestis, Valencia, CA) was per-
formed at the University of Michigan Hospital
laboratory; the results were reported as positive, inde-
terminate, or negative. This enzyme-linked immuno-
sorbent assay evaluates the interferon-c response of
peripheral lymphocytes to 2 MTB-specific antigens:
early secreted antigenic target 6 (ESAT-6) and culture
filtrate protein 10 (CFP-10).14 The test consists of a
negative control (a nil well: whole blood without anti-
gens or mitogen), a positive control (a mitogen well:
whole blood stimulated with the mitogen phytohemag-
glutinin), and 2 sample wells (whole blood stimulated
with either ESAT-6 or CFP-10). The response to phy-
tohemagglutinin is used as a positive control, and the
test is considered positive if the concentration of
interferon-c in the sample, after stimulation with
ESAT-6 and CFP-10, is greater than or equal to 0.35
IU/mL (regardless of the result of the positive control).
The result of the test is considered indeterminate if
both antigen-stimulated samples are negative and
if the value of the positive control is less than 0.5
IU/mL.
Evidence of latent TB infection was defined as either
a positive PPD skin test or a positive QFT test result.
The absence of latent TB was defined as a PPD result
<5 mm in maximal diameter or a QFT test that was
negative. If subjects had an indeterminate QFT test,
the results of all available follow-up studies, including
the medical history, chest imaging, and PPD test
results, were reviewed.
Treatment Protocol for Latent TB
Our treatment protocol for LT recipients with latent
TB includes isoniazid (300 mg/day) and pyridoxine
(50 mg/day). Treatment is to be initiated in the first
year after transplantation once the patient is clinically
stable, and the intended duration is 6 months with
monthly laboratory monitoring and assessment for
clinical symptoms of potential hepatotoxicity.
Statistical Analysis
Descriptive statistics of baseline clinical features were
determined for subjects with or without evidence of
latent TB. Kaplan-Meier survival curve analysis was
undertaken to determine pretransplant survival cen-
sored at the time of LT or pretransplant death in
latent TB–positive LT candidates versus latent TB–
negative LT candidates. Kaplan-Meier survival curve
analysis was also undertaken to determine posttrans-
plant survival in latent TB–positive LT recipients ver-
sus latent TB–negative LT recipients. Baseline charac-
teristics associated with posttransplant survival were
determined with Cox regression analyses. All data
analyses were performed with SPSS 10.0 (SPSS, Col-
lege Station, TX)
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RESULTS
Patient Population
From January 2004 to September 2008, 420 adult
patients who were listed for LT underwent PPD test-
ing; they represented more than 98% of the subjects
listed for LT during that time. In March 2008, QFT
testing became available and was implemented as the
preferred test. The QFT test results from March 2008
to October 2009 for 119 adult LT candidates were
available for review; they represented more than 99%
of the patients listed during that time.
PPD Test Results
Of the 420 adult LT candidates undergoing PPD test-
ing, 25 (6.0%) had a positive PPD result, and 395
(94.0%) had a negative result (Table 1). The mean age
of the 25 PPD-positive patients was 52.0 6 6.6 years;
14 (56%) were male; and there were 14 Caucasians
(56%), 6 African Americans (24%), 3 Hispanics (12%),
and 1 Asian American (4%). The primary liver diagno-
ses included hepatitis C (60%), alcohol (24%), and
various other diagnoses (16%); 8 patients (32.0%) had
hepatocellular carcinoma; and the mean MELD score
at listing was 15.8 6 6.4. During a mean follow-up of
41 months, 19 (76%) proceeded to LT, and 6 (24%)
were still awaiting transplantation. The mean ages,
percentages of males, MELD scores at listing, and
proportions undergoing transplantation were similar
for the PPD-positive subjects and the PPD-negative
subjects. However, the PPD-positive subjects were sig-
nificantly more likely to be non-Caucasian (44% ver-
sus 16.1%, P ¼ 0.00042). Finally, the PPD-positive
patients were significantly more likely to have hepati-
tis C versus the PPD-negative group (60% versus
38%, P ¼ 0.03) and significantly less likely to have
cryptogenic cirrhosis (0% versus 13.7%, P ¼ 0.048).
Clinical risk factors for TB infection were identified
during a retrospective chart review in only 6 (24%) of
the PPD-positive patients, including 3 patients with a
history of close personal contact with a known active
TB patient, 2 patients with overseas military service
in an endemic area, and 1 patient with a history of
occupational exposure as a health care worker. In
addition, only 2 (8%) of the PPD-positive patients had
radiographic evidence of latent TB infection. None of
the PPD-positive patients had been treated for active
TB in the past, and 3 had received a course of isonia-
zid chemoprophylaxis.
QFT Test Results
From March 2008 to October 2009, 11 (9.2%) of the
119 tested LT candidates had a positive QFT result,
15 (12.6%) had an indeterminate result, and 93
TABLE 1. Baseline Characteristics of the 420 Adult LT Candidates Undergoing PPD Testing
Feature PPD-Positive (n ¼ 25) PPD-Negative (n ¼ 395) P Value*
Age (years) 52.0 6 6.6 52.5 6 8.8 0.76
Male [n (%)] 14 (56) 243 (61) 0.58
Ethnicity [n (%)]
Caucasian 14 (56) 331 (84) 0.00042
African American 6 (24) 25 (6.3) 0.0011
Asian American 1 (4) 6 (1.5) 0.35
Hispanic 3 (12) 15 (3.8) 0.049
Other 1 (4) 18 (4.5) 0.90
White blood count (1000 cells/mL) 5.3 6 2.7 5.8 6 3.4 0.70
Country of origin [n (%)]
United States 23 (92) 381 (96.5) 0.26
Other 2 (8) 14 (3.5)
Liver diagnosis [n (%)]
Hepatitis C 15 (60)* 152 (38) 0.03
Alcohol 6 (24) 81 (21) 0.74
Primary sclerosing cholangitis 1 (4) 39 (9.9) 0.33
Hepatitis B 1 (4) 9 (2.3) 0.58
Cryptogenic 0 (0) 54 (13.7) 0.048
Other 2 (8) 60 (15.2) 0.33
Hepatocellular cancer [n (%)] 8 (32.0) 70 (17.7) 0.065
Laboratory MELD score at listing 15.8 6 6.4 16.4 6 6.6 0.68
Wait-list outcomes during follow-up [n (%)]
Underwent transplantation 19 (76) 245 (62) 0.067
Died before LT 0 (0) 61 (15) 0.034
Still waiting 6 (24) 89 (23) 0.86
Mean follow-up before LT (months) 11 6 18.7 12.3 6 16.9 0.78
NOTE: Data are reported as numbers and percentages or means and standard deviations.
*PPD-positive versus PPD-negative.
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(78.2%) had a negative result (Table 2). Although the
proportion with positive QFT test results was higher
than that seen with PPD testing, this trend was not
significant (9.2% versus 6.0%, P ¼ 0.204). The mean
age of the 11 QFT-positive patients was 54.0 6 11.1
years; 7 (63.6%) were male; and there were 4 Cauca-
sians (36.4%), 2 Asian Americans (18.2%), 3 African
Americans (27.3%), and 1 Hispanic patient (9.1%).
The primary liver diagnoses included hepatitis C
(36.4%), cryptogenic cirrhosis (27.3%), alcohol
(18.2%), and hepatitis B (9.1%), and only 1 patient
(9.1%) had hepatocellular carcinoma. The mean
MELD score at listing was 12.1 6 4.6. During a mean
follow-up of 10 months, 4 (36%) of the QFT-positive
patients proceeded to LT, whereas 1 (9%) died before
LT. The mean ages, percentages of males, etiologies of
liver disease, MELD scores at listing, and proportions
undergoing transplantation were similar in the QFT-
positive and QFT-negative groups. However, QFT-pos-
itive subjects were significantly more likely to be non-
Caucasian versus the QFT-negative patients (64%
versus 16%, P ¼ 0.006).
Between March 2008 and October 2009, 25 of the
119 patients who underwent QFT testing also under-
went PPD testing. The test results were concordant for
the presence of latent TB (QFT-positive/PPD-positive)
in 2 patients and for the absence of latent TB (QFT-
negative/PPD-negative) in 22 patients. In addition,
there were discordant test results for 1 patient who
was QFT-positive and PPD-negative.
Clinical risk factors for TB infection were identified
during a retrospective chart review in only 2 (18%) of
the 11 QFT-positive patients. In addition, only 3
(27%) had radiographic evidence of latent TB, and 1
of the QFT-positive patients had been previously
treated for active TB. While awaiting LT, 1 QFT-posi-
tive patient with a negative PPD test developed active
isoniazid-resistant MTB in a culture from a pleural bi-
opsy sample. This 49-year-old African American
female with cryptogenic cirrhosis presented with a
worsening right pleural effusion when her MELD
score was 11. She had never undergone testing for
latent TB and had not received any immunosuppres-
sion in the year to presentation. She likely acquired
latent TB in South Africa, where she had traveled fre-
quently as part of her occupation. The patient was
treated with ethambutol, rifabutin, and moxifloxacin
for 6 months, and her pleural effusion was resolved;
she is currently awaiting LT.
QFT-Indeterminate Patients
The ages, gender distributions, etiologies of liver dis-
ease, and ethnicities were similar for the 15 patients







(n ¼ 15) P Value*
Age (years) 54.0 6 11.1 53.6 6 8.4 45.6 6 10.3 0.90
Male [n (%)] 7 (63.6) 59 (63.4) 5 (33.3) 0.84
Ethnicity [n (%)]
Caucasian 4 (36.4) 74 (79.6) 9 (60.0) 0.00041
African American 3 (27.3) 8 (8.6) 3 (20.0) 0.057
Asian American 2 (18.2) 2 (2.2) 0 (0) 0.0086
Hispanic 1 (9.1) 2 (2.2) 2 (13.3) <0.05
Other 1 (9.1) 7 (7.5) 1 (6.7) 0.85
White blood count (1000 cells/mL) 5.7 6 2.3 5.9 6 2.8 6.3 6 2.4 0.13
Country of origin [n (%)]
United States 10 (91) 88 (94.7) 15 (100) 0.63
Other 1 (9) 5 (5.3) 0 (0)
Liver diagnosis [n (%)]
Hepatitis C 4 (36.4) 35 (37.6) 1 (6.7) 0.82
Alcohol 2 (18.2) 20 (21.5) 1 (6.7) 0.74
Primary sclerosing cholangitis 0 (0) 5 (1.1) 3 (20.0) 0.43
Hepatitis B 1 (9.1) 3 (3.2) 1 (6.7) 0.34
Cryptogenic 3 (27.3) 10 (10.8) 5 (33.3) 0.16
Other 1 (9.1) 20 (21.5) 4 (26.7) 0.33
Hepatocellular cancer [n (%)] 1 (9.1) 18 (19.4) 2 (13.3) 0.36
Lab MELD score at listing 12.1 6 4.6 15.9 6 6.8 20.7 6 10.8 0.078
Wait-list outcomes during follow-up [n (%)]
Underwent transplantation 4 (36) 42 (45) 11 (73) 0.58
Died before LT 1 (9) 10 (11) 0 (0) 0.87
Still waiting 6 (55) 41 (44) 4 (27) 0.51
Mean follow-up before LT (months) 5.04 6 6.18 4.16 6 2.18 3.84 6 5.4 0.54
NOTE: Data are reported as numbers and percentages or means and standard deviations.
*QFT-positive versus QFT-negative.
LIVER TRANSPLANTATION, Vol. 17, No. 3, 2011 JAFRI ET AL. 309
with indeterminate QFT test results and the QFT-neg-
ative group (Table 2). However, the QFT-indeterminate
patients had a significantly higher MELD score at list-
ing in comparison with both the QFT-positive patients
(20.7 6 10.8 versus 12.1 6 4.6, P ¼ 0.021) and the
QFT-negative patients (20.7 6 10.8 versus 15.9 6
6.8, P ¼ 0.023). Interestingly, for 6 (40%) of the QFT-
indeterminate patients, the test was performed while
they were hospitalized for a complication of cirrhosis.
A careful review showed that none of the QFT-indeter-
minate patients had clinical risk factors for latent TB
infection or radiological evidence of latent TB on chest
imaging, and none had been previously treated with
isoniazid. In addition, follow-up testing in 9 of these
patients showed negative PPD test results. Repeat
QFT testing was performed for 5 patients and showed
negative QFT results in 2 and persistent indetermi-
nate test results in 3. During follow-up, 11 (73%) of
the QFT-indeterminate patients underwent transplan-
tation with no evidence of TB reactivation during a
mean posttransplant follow-up period of 8 months.
Patient Survival and Latent TB Status
There was no significant difference in the transplant-
free survival rates of the 35 subjects with latent TB
and the 502 subjects without latent TB [hazard ratio
¼ 0.96, 95% confidence interval (CI) ¼ 0.64-1.44, P ¼
0.84; Fig. 1]. The mean 3-year transplant-free survival
rate was 19.7% in both groups. During follow-up, 321
(59.6%) of the 539 patients reviewed in this study
underwent LT, and this included 25 with latent TB
and 296 without latent TB. The posttransplant patient
survival rate of the 25 latent TB–positive patients was
similar to the survival rate of the 296 LT recipients
without latent TB (hazard ratio ¼ 0.75, 95% CI ¼
0.27-2.07, P ¼ 0.58; Fig. 2), with mean 3-year post-
transplant patient survival rates of 78.7% and 74.6%,
respectively.
Management of Latent TB After LT
To date, 15 (60%) of the 25 latent TB positive patients
have received isoniazid chemoprophylaxis along with
pyridoxine after transplantation. The mean time to
the initiation of isoniazid was 0.67 months after
transplantation (range ¼ 0-5 months). Seven of the 15
treated patients (46%) completed at least 6 months of
isoniazid therapy, whereas treatment was prematurely
discontinued in 8 subjects after a mean of 2.2
months. Reasons for early discontinuation of isoniazid
included concomitant thrombocytopenia in 3 patients,
poor compliance in 2, nausea and vomiting in 1, mild
rejection in 1, hepatotoxicity in 1, and high tacrolimus
troughs in 1. None of these 8 patients have been
retreated with isoniazid or alternative prophylactic
regimens. Notably, none of the 25 LT recipients with
latent TB demonstrated evidence of TB reactivation
during a mean follow-up of 34 months.
DISCUSSION
Immunosuppression greatly enhances the risk of TB
reactivation in patients with latent TB.15 Previous
studies have demonstrated a 0.3% to 15% incidence
of TB reactivation in solid organ transplant recipients,
which is 8- to 100-fold higher than that observed in
the general population.16 In one study, the median
time between transplantation and the development of
TB reactivation was 31 months.17 In another series,
LT recipients had an 18-fold increase in the risk of TB
reactivation and a 4-fold increase in the case fatality
rate in comparison with the general population.18 In
addition, the management of active TB infection in LT
recipients is complicated by the potential development
of drug hepatotoxicity from the recommended agents,
which can be difficult to distinguish from rejection
and other causes of allograft dysfunction as well as
potential drug interactions.19 Therefore, the accurate
diagnosis and management of organ transplant
Figure 1. Transplant-free survival in LT candidates with or
without latent TB infection. The actuarial transplant-free
survival rates were similar in the 35 patients with latent TB
infection and the 502 patients without latent TB infection
(hazard ratio ¼ 0.96, 95% CI ¼ 0.64-1.44, P ¼ 0.84).
Figure 2. Posttransplant survival in LT recipients with or
without latent TB infection. The posttransplant survival rate of
25 patients with latent TB infection was similar to the rate
observed for 296 patients without latent TB infection (hazard
ratio ¼ 0.75, 95% CI ¼ 0.27-2.07, P ¼ 0.58).
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candidates with latent TB are critical for optimizing
patient outcomes.
With an estimated prevalence of 0.5% to 3%, the
United States is considered a low-risk population for
individuals with latent TB infection.10,20 However, our
data indicate that at least 6% to 9% of consecutive
adult LT candidates have evidence of latent TB infec-
tion (Tables 1 and 2). Our data are consistent with
other reports from Western countries that demon-
strate a higher rate of latent TB infection among LT
candidates versus the general population (Table 3).
The reason for the higher rate of latent TB infection
may be the inclusion of many patients with alcoholic
liver disease, which is a commonly cited risk factor
for exposure to MTB in the United States.5,20 We also
noted a significantly higher rate of hepatitis C infec-
tion in the PPD-positive subgroup, which may be due
to the frequent presence of concomitant alcohol abuse
in LT candidates with hepatitis C virus.21 In addition,
ethnic minorities were significantly more common
among those with PPD-positive and QFT-positive test
results, and this is consistent with other studies of
the epidemiology of latent TB in the United States.20
Our data demonstrate a trend toward an increased
rate of detecting latent TB infection with the QFT
assay versus PPD testing. However, simultaneous
testing with both methods was performed only in 25
subjects in this series. Therefore, further assessment
of a larger independent LT patient population is
required to determine if one test has higher sensitivity
and specificity in LT candidates. Advantages of the
QFT assay include its objective and standardized
reporting features as well as the need for only a single
blood draw with no follow-up patient visit (a follow-up
visit is required for skin testing). However, the QFT
assay is not widely available and is more expensive
than PPD testing.5 Furthermore, its utility and validity
in patients with severe underlying illness have not
been established.22,23 Nonetheless, QFT testing is
believed to be more specific and less likely to lead to
false-positive tests due to the exposure of patients to
atypical mycobacteria or BCG vaccination.24 The
improved specificity of the QFT assay arises from its
inclusion of unique MTB proteins. However, our data
also demonstrate a relatively high rate of indetermi-
nate QFT test results versus that reported in the gen-
eral population (ie, 12.6% versus <1%). An indetermi-
nate QFT result is characterized by the absence of a
host immune response to both the control antigen
(phytohemagglutinin) and the MTB antigens. When
indeterminate test results are reported, a repeat test
is suggested to ensure that the result was not due to
improper specimen handling or storage. In the current
series, only 5 of the 15 subjects with indeterminate
results had repeat testing completed. The relatively
high rate of indeterminate test results for our LT can-
didates presumably is related to the generalized
anergy that severely ill patients with advanced liver
failure frequently manifest.7,25,26 In support of this,
the laboratory MELD scores of the indeterminate
group were significantly higher versus the other sub-
groups (Table 2). In addition, 40% of the patients with




















Country Spain United States United States Canada Germany United States
Test years 1988-1998 1988-1995 1988-1998 2006-2007 2004-2007 2004-2009
Tested patients (n) 373 918 273 153 48 539
Male (%) 60.9 NR 79.7 56 59.9




NR NR 81/3/13/3 NR 81/8/2/9
PPD-positive [n (%)] 89 (24) 14 (1.5) 46 (16.8) 37 (24.2) 6 (12) 25 (5.9)
QFT-positive [n (%)] ND ND ND 34 (22.2) 4 (8.3) 11 (9.2)
Liver disease (%) NR NR
Hepatitis C 48 25 38




Hepatitis B 10 12 3
Cryptogenic 0 15 13
Other 17 23 17
MELD score NR NR 13.6 6 4.4 16 (7-43) 16.3 6 6.8
NOTE: Data are reported as numbers and percentages, means and standard deviations, or medians and ranges. Fifteen
had active TB after LT, and 8 were only PPD-positive.
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indeterminate QFT test results were hospitalized
when they were tested, and studies have shown that
severely ill hospitalized patients frequently do not
respond adequately to control antigens.7,27 We sur-
mise that the subjects with indeterminate QFT test
results in our study were probably true negatives
without latent TB infection because none of the fol-
low-up PPD tests were positive, none had clinical risk
factors for MTB infection, and none developed TB
reactivation after transplantation. However, because
there is no gold standard test for latent TB, the inter-
pretation of indeterminate QFT tests remains uncer-
tain. The association of indeterminate QFT test
results with high MELD scores observed in our series
also highlights the importance of assessing latent TB
infection early on in patients with cirrhosis who may
ultimately require LT.
The transplant-free survival rate in the 35 LT candi-
dates with latent TB infection was similar to that
observed in the 502 patients without latent TB infec-
tion (Fig. 1). This is reassuring and indicates that
patients with latent TB are not more likely to develop
fatal complications with LT. However, preoperative
chest imaging of all LT candidates with latent TB
infection is recommended to exclude active TB infec-
tion. Notably, 1 latent TB patient developed TB reacti-
vation on the waiting list. Interestingly, this patient
did not have evidence of apical scarring on a chest
X-ray but rather had a typical right-sided pleural effu-
sion seen in many patients with cirrhosis. Fortu-
nately, a diagnosis of active TB infection was made
via pleural biopsy prompted by a positive QFT test,
and she was successfully treated with triple-drug
therapy and is currently awaiting LT. This individual
case demonstrates the incremental value of QFT test-
ing in detecting TB infection in patients with
advanced cirrhosis who have negative PPD results.
The posttransplant survival rate of the 25 latent TB
patients was similar to that observed in the 296 LT
recipients without latent TB infection (Fig. 2). The
generally favorable posttransplant outcomes that we
observed were similar to those in other series of LT
candidates with latent TB infection in the literature
(Table 4). In addition, none of our 25 subjects with
latent TB developed evidence of TB reactivation during
a mean follow-up of 33 months. Although our clinical
protocol was to treat all of these patients with isonia-
zid within the first year of transplantation, to date,
only 15 patients have been treated with isoniazid. The
administration of isoniazid early after transplantation
was difficult because of adverse events possibly
related to isoniazid, although the etiologies of high
tacrolimus levels and thrombocytopenia early after LT
are usually multifactorial and are not commonly
attributed to isoniazid use alone. In particular, prob-
lems in distinguishing acute rejection from drug hepa-
totoxicity make it difficult to use isoniazid within the
first 6 months after transplantation. Our high rate of
drug discontinuation is greater than that reported by
Benito et al.3 from Spain, who gave 23 patients isoni-
azid after transplantation. However, isoniazid still had
to be discontinued in 26% of the Spanish patients,


















Country United States United States United States Spain United States
Test years 1992-2001 2003-2006 1988-1995 1988-1998 2004-2009
Tested patients (n) 908 373 539
Patients positive for
latent TB (n)
18 14 8 89 25
Phase of isoniazid
therapy
Before LT Before LT After LT After LT After LT (<6 months)
Patients given
isoniazid (n)
18 5 8 23 15
Dose of isoniazid
(mg/day)
300 300 300 300 300
Intended duration of
isoniazid (months)
12 9 6 12 6
Patients discontinuing
isoniazid [n (%)]
0 (0) 2 (22) 0 (0) 6 (26) 8 (53)
Reasons for
discontinuation
Not applicable Hepatitis B virus
reactivation (1)
Hepatotoxicity (4) Thrombocytopenia (3)
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mostly because of hepatotoxicity (Table 4). Overall,
our data and those of others indicate that subjects
with latent TB should not be denied access to trans-
plantation because of concerns about greater post-
transplant morbidity and/or mortality.
Guidelines of the American Society of Transplanta-
tion recommend that all organ transplant candidates
undergo an evaluation for latent TB infection regard-
less of their BCG status.2 However, transplant centers
vary in their approach to the detection and treatment
of latent TB in LT candidates.28 In our study, the fre-
quency of clinical risk factors for latent TB was gener-
ally low in those who were PPD-positive (24%) and
QFT-positive (18%). Our retrospective data, obtained
through chart abstraction, likely underestimate the
true frequency of clinical risk factors because we were
not able to prospectively interview patients for poten-
tial TB exposures or travel or habitation in foreign
countries with a high rate of endemic TB. Some cen-
ters treat patients with latent TB in the pretransplant
period, others treat patients after transplantation,
and others simply observe the patient over time. Some
transplant centers neither test for nor treat latent TB
because of the perceived lack of efficacy and potential
toxicity of isoniazid in LT candidates.29,30 However, the
treatment of latent TB in LT patients with either isonia-
zid or rifampin is recommended because there is a
higher incidence of active TB in transplant patients
versus the general population, reactivation of latent TB
is the most common route of active infection, and the
mortality rate in LT recipients with TB reactivation is
as high as 30%.31-33 At the same time, the safety of che-
moprophylaxis has been questioned in LT recipients
because of the potential hepatotoxicity of both isonia-
zid and rifampin and potential drug interactions with
calcineurin inhibitors.34 The frequency and severity of
isoniazid hepatotoxicity in patients with decompen-
sated liver disease or after LT have not been well stud-
ied.34,35 However, asymptomatic serum alanine amino-
transferase elevations are seen in up to 25% of
immunocompetent patients receiving isoniazid mono-
therapy, but this may spontaneously resolve with con-
tinued treatment.36,37 Moreover, clinically overt and
potentially severe isoniazid hepatotoxicity also occurs
in 0.1% to 3% of adults.38,39 In fact, isoniazid hepato-
toxicity is the most commonly implicated agent leading
to drug-induced acute liver failure in the United States
and the most common reason that adults require emer-
gency LT for idiosyncratic drug hepatotoxicity.40,41 In a
recent systematic review, isoniazid treatment was asso-
ciated with a significant reduction in MTB reactivation
in LT patients versus no treatment (0.0% versus 8.2%,
P ¼ 0.02), and isoniazid hepatotoxicity occurred in only
6% of treated patients, with no reported deaths.18
Therefore, although the administration of isoniazid
before and after transplantation is difficult, the prepon-
derance of evidence supports its use in selected
patients with latent TB at high risk for reactivation.
In conclusion, our study results demonstrate that
QFT testing leads to a similar rate of detection of
latent TB infection in LT candidates versus historical
controls undergoing PPD testing. In the 25 subjects
who underwent both tests, the 2 tests performed simi-
larly. Our retrospective cohort data are consistent
with other reports and support the utility of consider-
ing this platform for the screening of LT candidates.6,7
However, our data also demonstrate a relatively high
rate of indeterminate QFT test results (ie, 12.6%), and
this will necessitate the development of a follow-up
algorithm in centers that adapt interferon-c release
assays as their preferred screening tests. Components
of this algorithm will likely include repeat QFT testing
to exclude laboratory error, PPD testing, a review of
the patient’s chest imaging and medical history, and
consultation with local infectious disease experts.42
The similar pretransplant and posttransplant out-
comes that we observed in patients with latent TB
infection and patients without latent TB infection,
combined with the results of other published reports,
indicate that latent TB infection should not exclude
individual patients from consideration for LT.2 Our
study findings also demonstrate the difficulty in
administering isoniazid to LT recipients in the early
posttransplant period and suggest that deferring iso-
niazid chemoprophylaxis until at least 6 months of
follow-up may be reasonable, but additional confirma-
tory studies are needed.
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